Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PT Kalbe Farma TbkFRA:LCLA +3.70%77 5-Year Yield-on-Cost % is 4.66 as of Jul. 19, 2026, which is 97% above its 10-year median of 2.36. GuruFocus rates FRA:LCLA with a GF Score™ of 77/100 and a GF Value™ of €0.06 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 514 Drug Manufacturers companies, PT Kalbe Farma Tbk ranks better than 63.81% on this metric.
PT Kalbe Farma Tbk's yield on cost for the quarter that ended in Mar. 2026 was 4.66.
The historical rank and industry rank for PT Kalbe Farma Tbk's 5-Year Yield-on-Cost % or its related term are showing as below:
FRA:LCLA'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 1.41 Med: 2.36 Max: 6.9
Current: 4.66
During the past 13 years, PT Kalbe Farma Tbk's highest Yield on Cost was 6.90. The lowest was 1.41. And the median was 2.36.
FRA:LCLA's 5-Year Yield-on-Cost % is ranked better than 63.81% of 514
companies
in the Drug Manufacturers industry
Industry Median: 2.325
vs FRA:LCLA: 4.66
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
PT Kalbe Farma Tbk 5-Year Yield-on-Cost % Related Terms
FRA:LCLA vs LLY, JNJ, ABBV: 5-Year Yield-on-Cost % Comparison
For the Drug Manufacturers - General subindustry, PT Kalbe Farma Tbk's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PT Kalbe Farma Tbk 5-Year Yield-on-Cost % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, PT Kalbe Farma Tbk's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where PT Kalbe Farma Tbk's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
PT Kalbe Farma Tbk (FRA:LCLA) has a 5-Year Yield-on-Cost % of 4.66 as of Jul. 19, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on PT Kalbe Farma Tbk and its competitors. This is 97% above median its historical median of 2.36. Over the past decade, PT Kalbe Farma Tbk's 5-Year Yield-on-Cost % has ranged from 1.41 to 6.90. According to the industry distribution chart, PT Kalbe Farma Tbk ranks #186 out of 514 companies in the Drug Manufacturers industry, placing it in the top 36.2%.
Is PT Kalbe Farma Tbk's 5-Year Yield-on-Cost % too high?
PT Kalbe Farma Tbk's current 5-Year Yield-on-Cost % of 4.66 is 97% above median its 10-year median of 2.36. Over the past 10 years, this metric has ranged from a low of 1.41 to a high of 6.90. The Drug Manufacturers industry median 5-Year Yield-on-Cost % is 2.33. PT Kalbe Farma Tbk's value of 4.66 is 100.4% above this industry median. Based on the distribution chart, PT Kalbe Farma Tbk ranks #186 out of 514 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, PT Kalbe Farma Tbk has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PT Kalbe Farma Tbk's 5-Year Yield-on-Cost % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, PT Kalbe Farma Tbk ranks #186 out of 514 companies for 5-Year Yield-on-Cost %. This puts PT Kalbe Farma Tbk in the upper half of its industry. The industry median 5-Year Yield-on-Cost % is 2.33. PT Kalbe Farma Tbk's value of 4.66 is 100.4% above this benchmark. Historically, PT Kalbe Farma Tbk's own 5-Year Yield-on-Cost % has ranged from 1.41 to 6.90 over the past decade. While the company's 10-year median is 2.36 vs. the industry median of 2.33, PT Kalbe Farma Tbk has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.33, based on 514 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PT Kalbe Farma Tbk's current 5-Year Yield-on-Cost % of 4.66 is 100.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on PT Kalbe Farma Tbk and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.33 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PT Kalbe Farma Tbk's current 5-Year Yield-on-Cost % is 4.66, which is 97% above median its own 10-year median of 2.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Kalbe Farma Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Kalbe Farma Tbk (FRA:LCLA) is currently considered Significantly Undervalued. The stock's GF Value™ is €0.06, compared to a current price of €0.03 — trading 53.3% below its estimated fair value. The current 5-Year Yield-on-Cost % is 4.66, which is 97% above median its 10-year median of 2.36 and 100.4% above the Drug Manufacturers industry median of 2.33. PT Kalbe Farma Tbk's overall GF Score™ is 77/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For PT Kalbe Farma Tbk (FRA:LCLA), the current 5-Year Yield-on-Cost % is 4.66 as of Jul. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Kalbe Farma Tbk (FRA:LCLA) Overvalued in 2026?
Based on GuruFocus' analysis, PT Kalbe Farma Tbk stock appears to be undervalued.
The current stock price of €0.03 is trading 53.3% below its estimated GF Value™ of €0.06.
GuruFocus considers PT Kalbe Farma Tbk to be Significantly Undervalued.
Key valuation signals for FRA:LCLA:
5-Year Yield-on-Cost %: 4.66 (97% above median its 10-year median of 2.36)
GF Value™: €0.06 vs. price of €0.03 (53.3% below fair value)
Industry Position: 100.4% above the Drug Manufacturers median (#186 of 514)
No single metric tells the full story. See the FRA:LCLA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PT Kalbe Farma Tbk is engaged in the development, manufacturing, and trading of pharmaceutical products, including human medicines and consumer health products. The company operates four segments: prescription pharmaceuticals, consumer health, Nutritionals, and distribution and logistics. The majority of the company's revenue is derived from the distribution and logistics segments. Its Product and Services are Prescription /Ethicals, Consumer Health, Nutritionals, Distribution & Logistics, Health Services, Medical Devices, and Others.
77GF Score
Get the complete analysis for FRA:LCLA
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:LCLA has been successfully added to your 
